- Start
- Jul 31, 202690% CONFIDENCEfrom the source
AbbVie Q2 2026: US$16.99 Billion Revenue as Skyrizi Hits US$5.5 Billion
- AbbVie delivered second-quarter net revenues of $16.990 billion, up 10.2 percent reported (9.5 percent operational), with adjusted diluted EPS of $3.65, up 22.9 percent[1][3]
- Immunology revenue was $8.786 billion, up 15.1 percent: Skyrizi $5.505 billion, Rinvoq $2.525 billion and Humira $756 million[1][3]
- Neuroscience revenue was $3.228 billion, up 20.3 percent, led by Vraylar at $1.071 billion and Botox Therapeutic at $1.042 billion[3]
- Pulse 2 reports first-half Skyrizi revenue of nearly $10 billion and Humira at $1.44 billion, down 37.2 percent[2]
- AbbVie cut its 2026 adjusted EPS guidance to $13.87 - $14.07 to include a $0.14 per share dilutive effect from the proposed Apogee acquisition[3]
References 484% CONFIDENCEOverall confidence: 84%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
The first entry is always the pin's source. Overall confidence is a weighted average of how firmly each reference supports the start and end times used above; a reference counts half as much for every 180 days older than the newest.
- [1]90%news.abbvie.com/2026-07-31-AbbVie-Reports-Second-Quarter-2026-Financial-Resultsnews.abbvie.com· Posted Oct 4, 2026· Starts Jul 31, 2026 ✓· 29% of score
AbbVie's release is titled 'AbbVie Reports Second-Quarter 2026 Financial Results' and dated July 31, 2026.
- [2]72%AbbVie: Skyrizi And Rinvoq Generate $8.03 Billion As Humira Revenue Falls 36% - Pulse 2pulse2.com· Added Oct 4, 2026· 29% of score
Secondary analysis of the quarter's immunology figures.[1]
- [3]92%AbbVie Reports Second-Quarter 2026 Financial Results (Form 8-K exhibit 99.1)sec.gov· Published Jul 31, 2026· 23% of score
The same release filed with the SEC[4].
- [4]85%AbbVie to Acquire Apogee Therapeutics (Form 8-K exhibit 99.1)sec.gov· Published Jun 22, 2026· 19% of score
Source of the Apogee deal referenced in the guidance change.[1]
Suggest a correction
Something missing or wrong? Say it in your own words: a link that backs this pin up, a different start or end date and why, or a fact it lacks or gets wrong. The AI checks it against this pin's sources, searches for better ones, and adds any page that backs you up. The pin's own sources still count most. A picture that shows something else, or shows it badly, is looked at too, and moved down or replaced.
